[8-K] Sanara MedTech Inc. Reports Material Event

Rhea-AI Filing Summary

Sanara MedTech Inc. announced its financial results for the quarter ended June 30, 2025 via a press release furnished as Exhibit 99.1 to this Current Report. The report explicitly states the press release is furnished rather than filed, and therefore the exhibit is not subject to Section 18 liability nor automatically incorporated by reference into other securities filings unless expressly stated.

The body of the Current Report contains no financial figures or performance metrics, so readers must consult Exhibit 99.1 for the company’s detailed results and any quantitative disclosures.

Sanara MedTech (ticker SMTI) is listed on the Nasdaq Capital Market and identifies its principal executive offices in Fort Worth, Texas.

Insights

Financial Analyst

TL;DR: Routine earnings disclosure furnished as an exhibit; the 8-K text contains no financial figures, limiting assessment of impact.

The Current Report notifies investors that Sanara MedTech furnished a press release with quarterly results for the period ended June 30, 2025, but it does not include any revenue, profit, cash flow, or guidance figures in the filing text. Because substantive financial metrics are absent from the 8-K itself, materiality and market impact cannot be evaluated from this document alone; the press release in Exhibit 99.1 must be reviewed to determine whether results are material.

Corporate Governance Expert

TL;DR: Company followed standard disclosure practice by furnishing rather than filing the press release, which limits Section 18 liability and incorporation.

The filing indicates compliance with customary disclosure mechanics: the company furnished the earnings press release as Exhibit 99.1 and included language clarifying that the exhibit is not "filed" and is not incorporated by reference unless expressly stated. This preserves the company’s narrower liability exposure for the exhibit content; however, the filing itself contains no operational or financial detail to assess governance or disclosure quality beyond that procedural statement.

false 0000714256 0000714256 2025-08-13 2025-08-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2025

SANARA MEDTECH INC.

(Exact name of registrant as specified in its charter)

Texas		001-39678		59-2219994
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer  Identification No.)

1200 Summit Avenue, Suite 414 Fort Worth, Texas		76102
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (817) 529-2300

(Former name or former address, if changed since last report)

Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

	☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		SMTI		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 13, 2025, Sanara MedTech Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release issued August 13, 2025 (furnished pursuant to Item 2.02).
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:	August 13, 2025
		Sanara MedTech Inc.
		By:	/s/ Elizabeth B. Taylor
		Name:	Elizabeth B. Taylor
		Title:	Chief Financial Officer

FAQ

What did Sanara MedTech (SMTI) disclose in this 8-K?

The company furnished a press release announcing financial results for the quarter ended June 30, 2025, included as Exhibit 99.1.

Where can I find the detailed Q2 2025 results for SMTI?

Detailed results are contained in Exhibit 99.1 (the press release); the Current Report text does not include financial figures.

Is the press release in the 8-K considered 'filed' with the SEC?

No. The report states the press release is furnished, not filed, and therefore is not subject to Section 18 liability or automatically incorporated by reference.

What exchange does Sanara MedTech (SMTI) trade on?

Sanara MedTech's common stock (SMTI) is listed on the Nasdaq Capital Market.

Who signed the Current Report on behalf of Sanara MedTech?

The Current Report is signed by Elizabeth B. Taylor, Chief Financial Officer of Sanara MedTech Inc.